Deep generative chemistry models emerge as powerful tools to expedite drug discovery. However, the immense size and complexity of the structural space of all possible drug-like molecules pose significant obstacles, which could be overcome with hybrid architectures combining quantum computers with deep classical networks. As the first step toward this goal, we built a compact discrete variational autoencoder (DVAE) with a Restricted Boltzmann Machine (RBM) of reduced size in its latent layer. The size of the proposed model was small enough to fit on a state-of-the-art D-Wave quantum annealer and allowed training on a subset of the ChEMBL dataset of biologically active compounds. Finally, we generated 2331 novel chemical structures with medicinal chemistry and synthetic accessibility properties in the ranges typical for molecules from ChEMBL. The presented results demonstrate the feasibility of using already existing or soon-to-be-available quantum computing devices as testbeds for future drug discovery applications.
Deep generative chemistry models emerge as powerful tools to expedite drug discovery. However, the immense size and complexity of the structural space of all possible drug-like molecules pose significant obstacles, which could be overcome with hybrid architectures combining quantum computers with deep classical networks. As the first step toward this goal, we built a compact discrete variational autoencoder (DVAE) with a Restricted Boltzmann Machine (RBM) of reduced size in its latent layer. The size of the proposed model was small enough to fit on a state-of-the-art D-Wave quantum annealer and allowed training on a subset of the ChEMBL dataset of biologically active compounds. Finally, we generated 2331 novel chemical structures with medicinal chemistry and synthetic accessibility properties in the ranges typical for molecules from ChEMBL. The presented results demonstrate the feasibility of using already existing or soon-to-be-available quantum computing devices as testbeds for future drug discovery applications.
The de novo design of drug molecules is recognized as a time-consuming and costly process, and computational approaches have been applied in each stage of the drug discovery pipeline. Variational autoencoder is one of the computer-aided design methods which explores the chemical space based on an existing molecular dataset. Quantum machine learning has emerged as an atypical learning method that may speed up some classical learning tasks because of its strong expressive power. However, near-term quantum computers suffer from limited num-ber of qubits which hinders the representation learning in high dimensional spaces. We present a scalable quantum generative autoencoder (SQ-VAE) for simultaneously reconstructing and sampling drug molecules, and a corresponding vanilla variant (SQ-AE) for better reconstruction. The architectural strategies in hybrid quantum classical networks such as, adjustable quantum layer depth, heterogeneous learning rates, and patched quantum circuits are proposed to learn high dimensional dataset such as, ligand-targeted drugs. Extensive experimental results are reported for different dimensions including 8x8 and 32x32 after choosing suitable architectural strategies. The performance of quantum generative autoencoder is compared with the corre-sponding classical counterpart throughout all experiments. The results show that quantum computing advantages can be achieved for normalized low-dimension molecules, and that high-dimension molecules generated from quantum generative autoencoders have better drug properties within the same learning period.
Existing drug discovery pipelines take 5–10 years and cost billions of dollars. Computational approaches aim to sample from regions of the whole molecular and solid-state compounds called chemical space, which could be on the order of1060. Deep generative models can model the underlying probability distribution of both the physical structures and property of drugs and relate them nonlinearly. By exploiting patterns in massive datasets, these models can distill salient features that characterize the molecules. Generative adversarial networks (GANs) discover drug candidates by generating molecular structures that obey chemical and physical properties and show affinity toward binding with the receptor for a target disease. However, classical GANs cannot explore certain regions of the chemical space and suffer from training instabilities. The practical utility of such models is limited due to the vast size of the search space, characterized by millions of parameters. A full quantum GAN may require more than 90 qubits even to generate small molecules with up to nine heavy atoms. The proposed quantum GAN with a hybrid generator (QGAN-HG) model is composed of a hybrid quantum generator that supports various number of qubits and quantum circuit layers, and a classical discriminator. The QGAN-HG with less than 20% of the original parameters can learn molecular distributions as efficiently as its classical counterpart. Another extended version of the proposed QGAN-HG, which utilizes multiple quantum subcircuits, considerably accelerates our standard QGAN-HG training process and avoids the potential gradient vanishing issue of deep neural networks.
The pharmaceutical industry faces mounting challenges in drug discovery, where exploring a chemical space exceeding 10 60 possible compounds remains computationally prohibitive. Traditional in-silico screening approaches struggle to capture the quantum mechanical interactions that determine molecular behavior. To overcome these limitations, this study introduces a hybrid quantum–classical machine learning framework that uniquely integrates molecular graph theory with quantum-enhanced learning for accelerated drug discovery. Using the QM9 benchmark dataset containing 133,885 molecules of low-to-medium structural complexity, we extract Laplacian eigenvalue spectra as topological descriptors that preserve both connectivity and electronic information. These features are jointly processed by Random Forest (RF), Support Vector Machine (SVM), and a Variational Quantum Classifier (VQC) in a weighted ensemble architecture designed for balanced generalization. The Quantum Graph Neural Network (QGNN) component achieves 97.5% accuracy, while the hybrid ensemble attains 100.0% accuracy, confirming strong predictive reliability. Although quantum training requires roughly 3.2× longer computation, it captures high-dimensional correlations that classical methods overlook. Overall, the proposed framework bridges the gap between theoretical quantum computing and practical pharmaceutical modeling, providing a scalable, physics-inspired pathway toward intelligent molecular screening and next-generation drug discovery systems.
Current drug discovery processes can cost billions of dollars and usually take five to ten years. People have been researching and implementing various computational approaches to search for molecules and compounds from the chemical space, which can be on the order of 1060 molecules. One solution involves deep generative models, which are artificial intelligence models that learn from nonlinear data by modeling the probability distribution of chemical structures and creating similar data points from the trends it identifies. These generative models can extract salient features that characterize the molecules. However, they often suffer from increased time complexity. Aiming for faster runtime and greater robustness when analyzing high-dimensional data, we designed and implemented a Hybrid Quantum-Classical Generative Adversarial Network (QGAN) to synthesize molecules. There are two parts in the QGAN: a quantum generator that creates molecules based on the probability distributions of likely combinations and a classical discriminator that differentiates real molecules from the generated ones. We hypothesized that a quantum generator would be more impactful, offering a runtime speedup and increasing generated molecule possibilities, because we could use quantum mechanical phenomena superposition, entanglement, and interference to analyze more atom-bond combinations than a classical generator. The PyTorch-PennyLane implementation of the QGAN generated seven chemically stable molecules out of 300, a 2.3% success rate. Although the QGAN is a work in progress, it has demonstrated a path towards more efficient drug development, which would accelerate the development of medicines and reduce costs for the whole R&D process.
De novo drug design with desired biological activities is crucial for developing novel therapeutics for patients. The drug development process is time- and resource-consuming, and it has a low probability of success. Recent advances in machine learning and deep learning technology have reduced the time and cost of the discovery process and therefore, improved pharmaceutical research and development. In this paper, we explore the combination of two rapidly developing fields with lead candidate discovery in the drug development process. First, artificial intelligence has already been demonstrated to successfully accelerate conventional drug design approaches. Second, quantum computing has demonstrated promising potential in different applications, such as quantum chemistry, combinatorial optimizations, and machine learning. This article explores hybrid quantum-classical generative adversarial networks (GAN) for small molecule discovery. We substituted each element of GAN with a variational quantum circuit (VQC) and demonstrated the quantum advantages in the small drug discovery. Utilizing a VQC in the noise generator of a GAN to generate small molecules achieves better physicochemical properties and performance in the goal-directed benchmark than the classical counterpart. Moreover, we demonstrate the potential of a VQC with only tens of learnable parameters in the generator of GAN to generate small molecules. We also demonstrate the quantum advantage of a VQC in the discriminator of GAN. In this hybrid model, the number of learnable parameters is significantly less than the classical ones, and it can still generate valid molecules. The hybrid model with only tens of training parameters in the quantum discriminator outperforms the MLP-based one in terms of both generated molecule properties and the achieved KL divergence. However, the hybrid quantum-classical GANs still face challenges in generating unique and valid molecules compared to their classical counterparts.
The convergence of Quantum Computing and Generative Artificial Intelligence (AI) marks a transformative leap in the field of drug discovery. Traditional drug development pipelines are often slow, costly, and limited by classical computational constraints. This paper presents a novel hybrid approach—QuantumGeneraDrug—that integrates quantum generative models with deep learning architectures to accelerate molecule generation, optimize binding affinities, and reduce computation time. A comprehensive literature survey highlights the evolution of both quantum algorithms and generative AI models applied to pharmaceutical research. The proposed system demonstrates improved performance over existing frameworks in key metrics such as valid molecule rate, druglikeness (QED) score, binding affinity accuracy, and processing time per compound. Comparative results are illustrated using numerical tables and visualized via bar and pie charts. The study concludes that Quantum Generative AI holds immense promise for next-generation drug discovery, especially in tackling complex diseases and enabling personalized medicine.